These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1098582)

  • 1. Single daily dose of allopurinol.
    Brewis I; Ellis RM; Scott JT
    Ann Rheum Dis; 1975 Jun; 34(3):256-9. PubMed ID: 1098582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose.
    Rodnan GP; Robin JA; Tolchin SF; Elion GB
    JAMA; 1975 Mar; 231(11):1143-7. PubMed ID: 1172813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and lack of toxicity of allopurinol (NSC-1390) given intravenously.
    Brown CH; Stashick E; Carbone PP
    Cancer Chemother Rep; 1970 Apr; 54(2):125-9. PubMed ID: 4946002
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of single daily dose allopurinol in gouty hyperuricemia.
    Rodnan GP; Robin JA; Tolchin SF
    Adv Exp Med Biol; 1974; 41():571-5. PubMed ID: 4832583
    [No Abstract]   [Full Text] [Related]  

  • 5. [Mechanism of the action of allopurinol].
    Pikhlak EG; Piliaev VG
    Sov Med; 1981; (10):111-4. PubMed ID: 7031905
    [No Abstract]   [Full Text] [Related]  

  • 6. Proceedings: Single daily dose of allopurinol.
    Brewis ID; Loebl WY; Scott JT
    Ann Rheum Dis; 1975 Apr; 34(2):201-2. PubMed ID: 1137459
    [No Abstract]   [Full Text] [Related]  

  • 7. [Allopurinol and gouty hyperuricemia : apropos of 30 cases treated by a single daily dose].
    Appelboom T; Famaey JP
    Brux Med; 1977 Mar; 57(3):133-7. PubMed ID: 861817
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of daily single doses of 300 mg allopurinol on serum uric acid concentration and urate excretion in gouty patients (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1974 Nov; 99(48):2464-5. PubMed ID: 4448143
    [No Abstract]   [Full Text] [Related]  

  • 10. The influence of allopurinol on the course of gout. A study of 28 cases.
    Kawenoki-Minc E; Eyman E; Sopata I; Weryńska-Przybylska J
    Reumatologia; 1970; 8(3):177-92. PubMed ID: 5469423
    [No Abstract]   [Full Text] [Related]  

  • 11. [Uric-acid reduction with high allopurinol dosages (author's transl)].
    Mertz DP; Loewer H
    Dtsch Med Wochenschr; 1979 Mar; 104(9):324-5. PubMed ID: 761542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Withdrawal of allopurinol in patients with gout.
    Scott JT; Loebl WY
    Adv Exp Med Biol; 1974; 41():577-9. PubMed ID: 4832584
    [No Abstract]   [Full Text] [Related]  

  • 13. [On the dose-effect relation of allopurinol (author's transl)].
    Mertz DP
    Arzneimittelforschung; 1977; 27(6):1209-11. PubMed ID: 578444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Mertz DP
    Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
    [No Abstract]   [Full Text] [Related]  

  • 16. [Allopurinol in the treatment of gout].
    Klein G; Griendl W; Kalb R
    Z Rheumaforsch; 1968 Dec; 27(11):455-60. PubMed ID: 5710881
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermittent control of hyperuricemia in the treatment of gout.
    Bull PW; Scott JT
    J Rheumatol; 1989 Sep; 16(9):1246-8. PubMed ID: 2681764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allopurinol: a comparative study of the bioavailability and effect on plasma uric acid of two products in tablet form.
    Nissen P; Pedersen L
    Biopharm Drug Dispos; 1985; 6(4):441-6. PubMed ID: 4084669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone.
    Kuzell WC; Seebach LM; Glover RP; Jackman AE
    Ann Rheum Dis; 1966 Nov; 25(6 Suppl):634-42. PubMed ID: 5335061
    [No Abstract]   [Full Text] [Related]  

  • 20. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.